139P First-in-human (FIH), pharmacokinetic (PK) and pharmacodynamic (PD) study of IOA-244, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in patients with advanced metastatic mesothelioma, uveal and cutaneous melanoma
Titel:
139P First-in-human (FIH), pharmacokinetic (PK) and pharmacodynamic (PD) study of IOA-244, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in patients with advanced metastatic mesothelioma, uveal and cutaneous melanoma
Auteur:
Di Giacomo, A.M. Santangelo, F. Amato, G. Simonetti, E. Graham, J. Lahn, M. Zorilla, R. van der Veen, L. Johnson, Z. Pickering, C. Maréchal, E. Blanco, J. Durini, M. Gufford, B. Lakshmikanth, T. Brodin, P. Spiliopoulou, P. Evans, T.R.J. Maio, M.